WORLD JOURNAL OF PHARMACEUTICAL RESEARCH
Coden USA: WJPRAP Impact Factor 8.453
Volume 14, Issue 21, 26-42. Review Article ISSN 2277–7105

REVIEW ARTICLE ON" IN SITU GEL FOR CYTOMEGALOVIRUS FOR OCULAR DELIVERY"

***Mr. P. Pramod Sangam, Dr. R. Yogananda, Chethan Patil DN, Sujay Yadav DK, S. Varun Shankar**

India.

Article Received on 01 Oct. 2025,
Article Revised on 21 October 2025,
Article Published on 01 Nov. 2025,

https://www.doi.org/10.5281/zenodo.17471517

***Corresponding Author**
Mr. P. Pramod Sangam
India.

How to cite this Article: *Mr. P. Pramod Sangam, Dr. R. Yogananda, Chethan Patil DN, Sujay Yadav DK, S. Varun Shankar (2025). REVIEW ARTICLE ON" IN SITU GEL FOR CYTOMEGALOVIRUS FOR OCULAR DELIVERY"World Journal of Pharmaceutical Research, 14(21), 26–42.

1. INTRODUCTION

1.1. Overview of in situ gel and Cytomegalovirus (CMV) Infections and Ocular Delivery Challenges

In situ gel delivery systems have become popular in pharmacy for providing continuous drug delivery without compromising visual clarity. These systems improve bioavailability, penetration, duration, and medication effectiveness compared to ointments. There are three main types: thermally triggered, pH-triggered, and ionic-strength-triggered systems. Temperature-sensitive hydrogels are commonly used, as they can gel at physiological temperatures, simplifying clinical handling without needing external heat. PH-sensitive gels change in response to surrounding pH, with polymers that either accept or release protons based on the pH.[1]

In situ gels are gaining interest as ocular drug delivery systems due to their easy application and sustained drug release. This review focuses on poloxamers, which are thermo responsive, biocompatible, and easy to sterilize, making them ideal for ocular delivery. Poloxamer-based gels can be tailored for sol-gel transition temperatures, mucoadhesion, and drug release, allowing them to deliver both small and large molecules for treating eye diseases. While some poloxamer-based ocular products are already available, there is still potential for further research and commercialization.[2]

A major challenge in ophthalmic drug delivery is achieving and maintaining the optimal drug concentration at the eye's site of action. Various dosage forms, such as solutions, ointments, gels, and polymeric inserts, have been explored to extend ocular residence time. While these

forms improve corneal contact time to some extent, they face issues like blurred vision (e.g., ointments) or poor patient compliance (e.g., inserts). Eye drops have low bioavailability due to rapid washout, and highly viscous solutions or gels can reduce patient compliance due to difficulty in administration. Blurred vision and excessive tearing are common issues with hydrogel-based formulations. To overcome the limitations in ophthalmic drug delivery, various dosage forms, such as solutions, ointments, gels, and polymeric inserts, have been explored to extend the ocular residence time and enhance the drug concentration at the site of action within the eye. Despite these efforts, these forms have not been universally accepted. The corneal contact time has been increased to varying degrees, but challenges remain, such as blurred vision (e.g., with ointments) or poor patient compliance (e.g., with inserts). Eye drops, while commonly used, suffer from very poor bioavailability due to rapid washout during lachrymation. Most systems are administered as solutions or suspensions, but conventional ocular formulations are rapidly eliminated from the pre-corneal area, resulting in poor drug bioavailability. Additionally, highly viscous solutions and gel forms may hinder ease of administration and reduce patient compliance, while hydrogel-based formulations are associated with blurred vision and lachrymation.[3]

2. In situ gel for ocular drug delivery

2.1. Overview of sol to gel phase transition mechanisms

In-situ gel formation occurs through mechanisms such as temperature, pH, and ion activation. Temperature-triggered systems utilize polymers that are liquid below their lower critical solution temperature (LCST) and gel upon reaching or exceeding this temperature. pH-induced gels contain polymers with acidic or alkaline groups that undergo sol-gel transitions in response to pH changes. Ion-activated systems, also known as osmotically triggered gels, transition from sol to gel due to changes in ionic concentration, typically induced by cations like Na^{+}, Mg^{2+}, and Ca^{2+} found in tear fluid. Additionally, gelation can be induced enzymatically or via photo polymerization. However, temperature, pH, and ion-induced in-situ gels are the most extensively studied approaches.[4]

2.2. Stimuli-responsive in-situ gel system

2.2.1. Temperature-triggered in-situ gel systems

Temperature-sensitive in-situ gels are among the most studied stimuli-responsive gels for ocular drug delivery. They can be introduced into the eye in liquid form without causing irritation or blurred vision. Upon reaching the precorneal temperature of approximately 35

°C, these gels undergo gelation, maintaining drug concentration at the site of action and minimizing rapid elimination. An ideal thermo-responsive ocular in-situ gel should have a gelation temperature above room temperature to avoid refrigeration before use, which could cause eye irritation due to coldness.[4]



The gelation process of thermo sensitive in-situ gelling. When the temperature is below the gelation temperature, it is clear solution with low viscosity, upon heating it to GT, the solution is converted to the gel with high viscosity.

2.2.2. Polymers used in the in situ gelling system

a) Pluronic F127: Pluronics (or Poloxamers) are non-ionic surfactants that form gels in response to temperature changes. They are triblock copolymers made of poly (oxyethylene) and poly (oxypropylene) units, with a hydrophobic core and hydrophilic outer segments. Their gelation properties vary based on the ratio of these subunits and molecular weight. For example, Pluronic F217 forms a transparent gel and is used in pharmaceuticals. At 25°C, a 20% concentration of F217 behaves as a viscous liquid but turns into a gel at 37°C. Poloxamer formulations help extend drug residence time, enhancing bioavailability and efficacy.

b) Gellan gum: Gellan gum (Gelrite®) is an anionic polysaccharide produced by *Pseudomonas elodea*, consisting of a tetrasaccharide repeating unit. It is produced via aerobic fermentation and isolated by alcohol precipitation. Gellan gum gels through temperature changes or cation-induced processes, forming a 3D network via double helix junctions and aggregation. In the stomach, calcium ions trigger gelation in acidic

conditions, while in ophthalmic applications, contact with tear fluid's cations (Na+, K+, Ca2+) causes gel formation.

c) **Alginic acid:** Alginic acid is a linear polysaccharide made up of β-D-mannuronic acid and α-L-guluronic acid linked by 1, 4-glycosidic bonds. Its structure varies depending on the algal source. When diluted in water, alginates form strong gels in the presence of divalent and trivalent metal ions. Alginic acid is mucoadhesive, biodegradable, and non-toxic, making it ideal for use in ophthalmic in situ gelling systems.

d) **Pectin:** Pectins are polysaccharides with a backbone of α-(1, 4)-D-galacturonic acid residues. Low methoxy pectins (with a degree of esterification <50%) form gels in the presence of free calcium ions, following the egg-box model. While gelation can occur with H+ ions, calcium ions are typically needed for drug delivery gels. Pectin's water solubility allows it to be used without organic solvents. When taken orally, divalent cations in the stomach trigger pectin gelation, and pectin has been shown to sustain the delivery of paracetamol.

e) **Xyloglucan**: Xyloglucan is a polysaccharide from tamarind seeds, consisting of a β-D-glucan backbone with α-D-xylose branches, some of which are substituted by β-D-galactoxylose. When partially degraded by β-galactosidase, xyloglucan forms thermally reversible gels through lateral stacking of its rod-like chains. These gels form when heated to body temperature and have potential uses in oral, intraperitoneal, ocular, and rectal drug delivery.

f) **Xanthum gum**: Xanthan gum is a high molecular weight polysaccharide produced by fermenting *Xanthomonas campestris*. Its structure includes a cellulose backbone with a trisaccharide side chain of β-D-mannose-β-D-guluronic acid-α-D-mannose. Xanthan gum has been tested for creating sponge-like in situ gelling inserts for nasal drug delivery, particularly for proteins and peptides. Bioadhesive polymers are used to enhance nasal residence time, overcoming mucociliary clearance, and allowing drugs to be embedded in the porous sponges.

g) **Synthetic polymers:** Synthetic polymers are increasingly being explored for use in drug delivery, particularly in parenteral (injectable) formulations. A major trend in this area is the development of **biodegradable polymers** that do not require surgical removal once the drug has been released, making treatments less invasive and more convenient. Among these, **aliphatic polyesters**—such as poly (lactic acid), poly (glycolic acid), poly (lactide-co-glycolide), poly (decalactone), and poly (ε-caprolactone)—have been widely studied. In addition to these, **triblock copolymers** (e.g., poly (D, L-lactide)-block-poly (ethylene

glycol)-block- poly (D, L-lactide)) are used in **injectable in situ systems**, where the formulation turns into a solid or gel after injection to release the drug over time. These systems are especially effective for the **controlled release of bioactive agents**. Another innovative approach involves **in situ cross-linking polymers**, which form a network structure when activated by light or heat, creating a stable depot for sustained drug delivery inside the body.[5]

3. Research gaps in ocular drug delivery for CMV

3.1. Limited focus on posterior segment

3.1.1. Challenges in targeting the posterior segment of the eye for the CMV retinis need for sustained release systems for segment diseases

Targeting the **posterior segment of the eye**, especially for conditions like **CMV retinitis (Cytomegalovirus retinitis)**, poses several challenges that highlight the need for **sustained release drug delivery systems**. The posterior segment, which includes the retina, choroid, and vitreous humor, is difficult to access due to the **eye's unique anatomy and protective barriers**, such as the **blood-retinal barrier**. Traditional topical or systemic drug administration often results in **insufficient drug concentration** reaching the affected area. Frequent **intravitreal injections**, while more direct, can lead to complications like infection, retinal detachment, and patient discomfort. Therefore, **sustained release systems**, such as biodegradable implants or injectable in situ-forming polymers, are essential. These systems allow for **long-term, controlled drug delivery** directly to the posterior segment, reducing the need for repeated interventions and improving treatment outcomes for chronic or infectious diseases like CMV retinitis.[6]

3.2. Lack of ion and pH activated in situ gels

3.2.1. Research gaps in dual activated in situ gel systems for ocular delivery

Dual ion- and pH-responsive in situ gels show promise for ocular drug delivery, but several significant research gaps limit their broader application, especially for targeting the **posterior segment of the eye** (e.g., retina, choroid). Most current formulations are designed for **anterior segment diseases**, as delivering drugs to deeper tissues remains difficult due to **poor penetration and lack of targeting strategies**. These systems must activate within the eye's **narrow physiological pH (7.0–7.4)** and **ionic range**, which makes it challenging to design gels that are sensitive enough to trigger gelation without being too unstable or prematurely activated. Furthermore, although they perform well in lab tests, their **gelation**

and mucoadhesion may be disrupted in real conditions by blinking, tear fluid, and drainage, requiring more in vivo performance data. Another concern is the **stability of drugs**—especially sensitive molecules like peptides—which may degrade or lose activity when combined with ion- or pH-reactive polymers. Achieving **controlled, sustained release** is also complex when two stimuli are involved, often resulting in **burst release** or incomplete delivery. **Long-term safety data** are limited, and there's uncertainty about potential **irritation or toxicity** from chronic use, particularly in high-risk patient groups. Additionally, **formulation challenges** related to sterility, shelf life, and industrial scalability have not been fully addressed. Finally, despite encouraging lab results, these systems have **yet to reach clinical trials**, highlighting a critical need for translational studies and regulatory guidance to support their real-world use.[7]

3.2.2. Potential of ion activated systems for enhanced drug retention and release:

The **potential of ion-activated in situ gel systems** as an innovative approach to enhance **ocular drug retention and sustained release**, addressing the limitations of conventional eye drops. Traditional eye medications often suffer from poor bioavailability due to rapid tear drainage and limited corneal contact time. In contrast, ion-activated in situ gels remain in a **liquid state before administration** and **undergo gelation upon contact with tear fluid**, which contains **ions like Na^+ and Ca^{2+}**. This ionic trigger enables a **sol-to-gel transition** that prolongs precorneal residence time, thereby enhancing drug bioavailability and therapeutic effect.

The article discusses several **ion-sensitive polymers** such as **gellan gum, sodium alginate, and chitosan**, which are capable of forming hydrogels upon interaction with tear electrolytes. These polymers not only facilitate sustained drug release but also improve patient compliance by reducing the frequency of administration. Formulations using **Gelrite (gellan gum)**, often in combination with viscosity enhancers like HPMC, have shown **rapid gelation, good ocular tolerability, and minimal irritation**. Studies have confirmed that such gels can sustain drug release for **up to 6 hours or more**, depending on the polymer concentration and drug type.

Moreover, ion-activated in situ gels are highly adaptable, being successfully formulated for drugs like **ciprofloxacin, ketorolac, scopolamine, and levofloxacin**, targeting conditions ranging from **bacterial conjunctivitis** to **motion sickness**. Evaluations such as **rheological**

analysis, in vitro release, corneal permeation, and irritation studies support their safety and efficacy.[8]

3.3. Unexplored nanotechnology and dendrimers

3.3.1. Limited integration of nanotechnology (eg: dendrimers) with in situ gel systems for CMV delivery

The integration of nanotechnology, specifically dendrimers, with in situ gel systems for Cytomegalovirus (CMV) delivery holds significant promise but faces several challenges that limit its practical application. Dendrimers, with their high drug-loading capacity, controlled release properties, and enhanced permeability, could greatly improve drug delivery systems for CMV. However, issues such as the compatibility between dendrimers and gel formulations, stability, drug release control, and targeted penetration into ocular tissues complicate their use. Dendrimers may interfere with the gel's ionic interactions, leading to instability and improper drug release. Additionally, achieving sustained, localized drug release, particularly in the posterior eye segment, is difficult with dendrimer- based systems. Moreover, concerns about dendrimer toxicity and immune responses pose safety risks, particularly for ocular applications. To address these challenges, potential strategies include modifying dendrimers with PEG for improved biocompatibility, developing hybrid gel systems for more controlled drug release, crosslinking dendrimers with gel components to enhance stability, and functionalizing dendrimers for targeted delivery to infected ocular tissues. These approaches could pave the way for more effective and safer CMV treatments.[9]

3.3.2. Potential of nanoparticle-laden hydrogels for improved corneal penetration

Despite promising advancements, several critical gaps hinder the clinical translation of nanoparticle-laden in situ gels for ocular drug delivery. Firstly, there is a limited understanding of the detailed mechanisms by which nanoparticles interact with corneal tissues, including cellular uptake and drug transport across the epithelium. This makes it difficult to predict performance and optimize formulations. Secondly, while many studies report enhanced outcomes in vitro, these models often fail to replicate the complexity of the human eye. As a result, there is a need for more reliable **in vivo studies** and better **in vitro–in vivo correlation (IVIVC)**. Another major challenge is the long-term **biocompatibility and safety** of the nanoparticles and gel systems, particularly with repeated dosing—data here are still scarce. In terms of formulation, ensuring **stability**, **sterilization**, and **scalability** of nanoparticle-in-gel systems remains problematic, especially since many of these components

are sensitive to heat and shear. Lastly, regulatory pathways for such hybrid systems are underdeveloped, posing obstacles to clinical approval. These gaps highlight the need for more mechanistic studies, robust preclinical validation, and standardized guidelines to support the development of safe, effective, and commercially viable ocular Nano medicine.[10]

3.4. Biodegradable Polymers for Targeted Delivery

3.4.1. Research gaps in the use of biodegradable polymers (e.g., PLGA, chitosan) for targeted CMV delivery

Although antiviral agents such as acyclovir triphosphate, cidofovir, and foscarnet are effective against cytomegalovirus (CMV) infections, their conventional administration routes—primarily intravenous or oral—are associated with systemic toxicity, limited ocular bioavailability, and poor patient compliance. Biodegradable polymers such as poly (lactic-co-glycolic acid) (PLGA) and chitosan offer promising platforms for localized and sustained drug delivery, especially in ocular applications. However, significant research gaps remain regarding their use in targeted CMV therapy. First, there is limited exploration of how these polymers can be optimized to encapsulate unstable molecules like nucleotide analogs (e.g., acyclovir triphosphate), which are prone to degradation. Second, the interaction between CMV-targeted antivirals and the polymer matrix, including release kinetics and drug-polymer compatibility, has not been thoroughly investigated. Third, despite the potential of these systems to bypass systemic exposure and reduce side effects such as nephrotoxicity or bone marrow suppression, in vivo studies evaluating the safety, efficacy, and bio distribution of polymer-based ocular formulations are sparse. Moreover, the ability of polymeric systems to achieve site-specific delivery to the posterior segment of the eye, where CMV retinitis often occurs, remains technically challenging and poorly documented. Finally, there is a lack of comparative research analysing biodegradable polymer-based delivery systems versus current standard treatments, which is necessary to establish clinical relevance. Addressing these gaps is critical to advancing the use of biodegradable polymers for effective, safe, and targeted CMV treatment.[11]

3.4.2. Need for biodegradable Nano carriers to enhance drug bioavailability

The use of biodegradable Nano carriers in ocular in situ gel systems is increasingly recognized as a necessary advancement to overcome the challenges of poor drug bioavailability in ocular drug delivery. The eye's unique anatomy and physiology—such as tear turnover, blinking, and limited permeability of the corneal epithelium—significantly restrict

the residence time and absorption of topically applied drugs. While in situ gels improve precorneal retention by undergoing a sol-to-gel transition upon contact with ocular stimuli (e.g., temperature, pH, or ions), they often lack the ability to efficiently solubilize and stabilize hydrophobic or labile drugs. Biodegradable Nano carriers, such as those made from PLGA, chitosan, or lipid-based materials, can encapsulate these drugs, protect them from enzymatic degradation, and enable a sustained, controlled release directly at the ocular surface. When incorporated into in situ gels, these Nano carriers create a synergistic delivery platform that enhances drug penetration, prolongs therapeutic action, reduces dosing frequency, and minimizes systemic exposure and side effects. This approach is especially important for treating chronic ocular conditions such as cytomegalovirus retinitis or herpetic keratitis, where consistent, localized delivery is critical for efficacy and patient compliance. Therefore, the combination of biodegradable Nano carriers and in situ gels offers a robust solution to enhance drug bioavailability in ocular therapies.[12]



4. Advanced Formulations for CMV Ocular Delivery

4.1. Ion- and pH-Activated in Situ Gels

4.1.1. Design and evaluation of dual-activated in situ gels for sustained drug release study: Timolol maleate delivery using chitosan and gellan gum

The design and evaluation of dual-activated in situ gels using chitosan and gellan gum for the sustained delivery of timolol maleate represent a promising advancement in ocular drug delivery, particularly for managing glaucoma. This system leverages the combined benefits of pH-sensitive and ion-sensitive gelation mechanisms. Chitosan, a biocompatible polymer, responds to the physiological pH of the tear fluid (~7.4) to form a gel, while gellan gum undergoes ion-induced gelation in the presence of cations like calcium found naturally in the eye. Together, these polymers enable the formulation to remain in a liquid state during administration and rapidly transform into a gel upon contact with the eye, increasing its retention time on the ocular surface.

This dual-triggered system ensures that timolol maleate is released in a controlled and sustained manner, improving its bioavailability and therapeutic efficacy compared to conventional eye drops, which are quickly cleared by blinking and tear turnover. The in situ gel also enhances patient compliance by reducing the need for frequent dosing. Moreover, the use of biodegradable and non-toxic materials like chitosan and gellan gum ensures the safety and tolerability of the formulation. Overall, this approach addresses key limitations in ophthalmic drug delivery and offers a more effective solution for treating chronic eye conditions like glaucoma.[13]

4.2. Thermo responsive in Situ Gels

4.2.1. Formulation and evaluation of thermo responsive gels using Pluronic and sodium alginate

The formulation and evaluation of thermo responsive gels using Pluronic F127 and sodium alginate aim to develop an effective transdermal delivery system for drugs like selegiline, which suffers from variable absorption and side effects in conventional forms. Pluronic F127 (a triblock copolymer of poly (ethylene oxide)-poly (propylene oxide)-poly (ethylene oxide)) is a well-known thermo responsive polymer that exists as a free-flowing solution at room temperature but transitions into a semi-solid gel at body temperature. However, Pluronic gels alone have limitations such as low mechanical strength and lack of biodegradability. To overcome these issues, sodium alginate—a natural, biodegradable, and biocompatible polysaccharide—was incorporated to form a composite hydrogel. This combination enhances the structural integrity and biocompatibility of the gel system.

The formulation process involved synthesizing a graft copolymer by chemically linking monoamine-terminated Pluronic F127 to the alginate backbone via EDC/NHS-mediated crosslinking. This modification delayed the gelation temperature of the system, making it more suitable for topical or transdermal applications, especially in warmer climates where premature gelation could be problematic. The resulting thermo sensitive hydrogel remains a liquid at room temperature for easy administration and transforms into a gel upon reaching skin temperature, allowing for prolonged retention and sustained drug release.



The development of thermo responsive gels utilizing Pluronic F127 and sodium alginate offers a promising approach for controlled drug delivery systems. These gels exhibit sol-to-gel transition at physiological temperatures, enhancing the retention and sustained release of therapeutic agents. Pluronic F127, a triblock copolymer, undergoes a reversible gelation process upon heating, forming a gel at body temperature, which is beneficial for localized drug delivery. Sodium alginate, a natural polysaccharide, contributes to the gel's mechanical strength and biocompatibility.[14]

4.3. Nanotechnology and Dendrimers

Dendrimers and stimulus-responsive nanoparticle-laden hydrogels are two advanced Nano carrier systems showing great promise in ocular drug delivery. Dendrimers are highly branched, Nano sized polymers that enhance ocular drug delivery through their ability to improve drug solubility, provide controlled release, and increase corneal and conjunctival penetration, while also allowing surface modification for targeted therapy. On the other hand, stimulus-responsive hydrogels embedded with nanoparticles respond to specific ocular triggers such as pH, temperature, or enzymes to release drugs in a controlled and site- specific manner. These hydrogels prolong drug residence time on the ocular surface and enable enhanced corneal penetration by protecting and steadily releasing nanoparticle- encapsulated drugs, thereby improving therapeutic outcomes for various anterior segment eye diseases. Together, these technologies represent a significant advancement in overcoming the barriers of conventional eye drop formulations.[15]



5. Clinical and Patient-Centered Considerations

5.1. Clinical Efficacy and Safety

In vivo evaluation of in situ gelling systems for the treatment of CMV retinitis primarily involves assessing their ocular safety, retention, and potential irritation using established toxicity models. The most traditional method is the **Draize test**, in which a small volume (0.1 ml) of the formulation is instilled into the conjunctival sac of rabbit eyes, and ocular tissues such as the cornea, iris, and conjunctiva are observed for signs of irritation or damage over a period of several days. While this test provides insight into local tolerance, it has been heavily criticized for ethical reasons due to the pain it causes and its limited relevance to human eye anatomy. As a more humane refinement, the **low-volume eye irritation test (LVET)** was developed, using smaller amounts of the substance (0.01 ml) applied directly to the corneal center, improving biorelevance while still relying on animal testing.

To reduce the reliance on animal studies, **ex vivo models** such as the **Hen's Egg Test–Chorioallantoic Membrane (HET-CAM)**, **Bovine Corneal Opacity and Permeability (BCOP)** test, and **isolated eye tests (IRE and ICE)** have been adopted. These methods allow evaluation of irritation potential by measuring effects like haemorrhage, lysis, and opacity on non-living tissues or organs. HET-CAM, in particular, is widely used in screening in situ gels made from biopolymers, as it offers a good correlation with in vivo data. However, these tests cannot measure lesion reversibility.

In vitro methods further support safety evaluation by focusing on cytotoxicity using cultured ocular cells. For example, the **MTT assay** measures cell viability based on mitochondrial enzyme activity and can determine whether a formulation damages corneal or conjunctival cells. The **Short Time Exposure (STE)** test, using a rabbit corneal cell line (SIRC), evaluates toxicity after brief exposure, mimicking realistic human contact durations. Although no single

in vitro test fully replaces the Draize test, combinations of these methods provide valuable safety data. Studies have shown that in situ gelling systems formulated with polymers like gellan gum or sodium alginate are generally non-irritant, and any observed toxicity is usually due to the active drug rather than the gel matrix. Therefore, a combination of in vivo, ex vivo, and in vitro models is often used to comprehensively assess the ocular safety and irritation potential of in situ gels intended for diseases like CMV retinitis.[16]

5.2. Patient Compliance and Comfort

In situ ocular gels offer distinct advantages over conventional eye drops and ointments, particularly in the treatment of chronic eye conditions like CMV retinitis. Unlike conventional formulations, which are quickly cleared from the eye due to blinking and tear drainage, in situ gels undergo a sol-to-gel transformation upon contact with the ocular surface. This transformation significantly extends the **residence time** of the drug, allowing for sustained contact with the eye and improving the potential for drug absorption. As a result, these gels provide **enhanced bioavailability**, ensuring that more of the active drug reaches the target tissue and stays effective for a longer duration.

One of the most significant impacts of in situ gels is on **patient compliance**. Traditional eye drops often need to be applied multiple times a day due to their short duration of action, which can be inconvenient and lead to poor adherence. In contrast, in situ gels release the drug gradually over time, thereby **reducing the frequency of administration**. This less burdensome regimen improves the likelihood that patients will follow their treatment plans consistently. Additionally, the gel form minimizes **systemic absorption**, reducing the risk of side effects beyond the eye. The **controlled and precise drug delivery** of in situ gels also helps maintain therapeutic drug levels without causing peaks or troughs, reducing the chances of under- or overdosing. Furthermore, the gel matrix can **protect sensitive drugs** from premature degradation caused by enzymes or tear fluid, ensuring more of the drug remains intact until it reaches the intended site of action. Overall, the **prolonged release and targeted delivery** of in situ gels contribute to better **therapeutic outcomes**, improved **patient comfort**, and **higher compliance**, making them a superior alternative to conventional ocular treatments.[17]

6. Future Directions

6.1. Emerging Trends in In Situ Gel Technology

Recent advancements in in situ gel technology for ocular drug delivery have introduced several innovative trends aimed at improving therapeutic efficacy, patient comfort, and formulation flexibility. One major development is the use of **stimuli-responsive polymers** that undergo gelation in response to temperature, pH, or ionic strength, allowing for site-specific and controlled drug release. Building on this, **multi-stimuli responsive systems** have emerged, capable of reacting to more than one physiological trigger, which enhances the precision and adaptability of drug delivery. Another significant trend is the incorporation of **nanoparticles**—such as liposomes, Nano emulsions, and solid lipid nanoparticles—into in situ gels. These hybrid systems improve drug solubility, prolong release, target specific ocular tissues, and reduce side effects.

There is also a growing focus on using **natural and biodegradable polymers**, like chitosan, alginate, and hyaluronic acid, which offer improved biocompatibility and reduced ocular irritation, making them safer for long-term use. Additionally, researchers are exploring **combination therapy gels** that can deliver multiple drugs simultaneously, a promising strategy for treating complex eye diseases such as CMV retinitis or glaucoma with fewer applications. Another emerging approach involves the use of **3D printing technologies** tocreate personalized in situ gels tailored to individual patient needs, enhancing precision medicine in ophthalmology. Furthermore, novel delivery formats such as **ocular inserts and film-forming gels** are being developed to increase drug retention time and provide sustained drug release. Lastly, there is an increasing emphasis on **green chemistry and sustainable materials**, reflecting the industry's shift toward eco-friendly and regulatory- compliant formulations. Altogether, these trends represent a significant leap forward in making ocular treatments more effective, targeted, and patient-friendly.[18]

7. CONCLUSION

In situ gel technology has emerged as a promising strategy in ocular drug delivery, particularly for chronic and hard-to-reach conditions like Cytomegalovirus (CMV) retinitis. These systems offer significant advantages over conventional eye drops and ointments, including prolonged residence time, enhanced drug bioavailability, targeted delivery, reduced administration frequency, and improved patient compliance. By utilizing physiological triggers such as temperature, pH, or ionic strength, in situ gels can transition from a liquid to

a gel upon contact with the eye, ensuring better localization and sustained drug release. The incorporation of polymers like Pluronics, gellan gum, alginic acid, and synthetic biodegradable carriers such as PLGA further improves gel performance by enhancing stability, biocompatibility, and controlled drug release.

Key Findings and Research Gaps

Despite substantial progress, several research gaps remain. First, most current in situ gel systems are tailored for anterior segment diseases; effective delivery to the posterior segment, where CMV retinitis occurs, is still limited. Dual-responsive systems (e.g., ion and pH-sensitive gels) show promise but face challenges in gelation stability, drug compatibility, and in vivo performance. Second, nanotechnology, including dendrimer and nanoparticle integration with in situ gels, holds great potential but is underexplored due to issues related to formulation stability, safety, and regulatory approval. Third, while biodegradable polymers like PLGA and chitosan offer advantages for targeted, localized delivery, their application for encapsulating antiviral agents needs further optimization. Finally, there is a lack of robust in vivo and clinical data supporting these novel systems, and more translational research is needed to bridge laboratory findings with real-world applications.

Future Prospects

The future of in situ gel technology lies in multi-stimuli responsive systems, the use of natural and eco-friendly polymers, and personalized medicine through 3D printing and advanced formulation techniques. Incorporating nanotechnology, such as nanoparticle- laden hydrogels and dendrimer complexes, will be key to overcoming ocular barriers and improving drug retention and penetration, especially in posterior eye diseases. Furthermore, exploring combination therapies and hybrid delivery platforms will allow treatment of complex ocular conditions with fewer side effects and better therapeutic outcomes. For successful clinical translation, future research must focus on refining formulation stability, ensuring safety through long-term studies, and developing regulatory frameworks for these advanced drug delivery systems. Overall, in situ gels represent a transformative shift in ocular pharmacotherapy with great potential to improve patient outcomes and quality of life.

REFERENCES

1. Almeida H, Amaral MH, Lobão P, Lobo JM. In situ gelling systems: a strategy to improve the bioavailability of ophthalmic pharmaceutical formulations. Drug discovery today, 2014 Apr 1; 19(4): 400-12.

2. Soliman KA, Ullah K, Shah A, Jones DS, Singh TR. Poloxamer-based in situ gelling thermoresponsive systems for ocular drug delivery applications. Drug Discovery Today, 2019 Aug 1; 24(8): 1575-86.
3. Makwana SB, Patel VA, Parmar SJ. Development and characterization of in-situ gel for ophthalmic formulation containing ciprofloxacin hydrochloride. Results in pharma sciences, 2016 Jan 1; 6: 1-6.
4. Wu Y, Liu Y, Li X, Kebebe D, Zhang B, Ren J, Lu J, Li J, Du S, Liu Z. Research progress of in-situ gelling ophthalmic drug delivery system. Asian journal of pharmaceutical sciences, 2019 Jan 1; 14(1): 1-5.
5. Devasani SR, Dev A, Rathod S, Deshmukh G. An overview of in situ gelling systems. Pharmaceut Biolog Evaluat, 2016; 3(1): 60-9.
6. Gabai A, Zeppieri M, Finocchio L, Salati C. Innovative strategies for drug delivery to the ocular posterior segment. Pharmaceutics, 2023 Jul 1; 15(7): 1862.
7. Gupta H, Velpandian T, Jain S. Ion-and pH-activated novel in-situ gel system for sustained ocular drug delivery. Journal of drug targeting, 2010 Aug 1; 18(7): 499-505.
8. Kurniawansyah IS, Rusdiana TA, Wahab HA, Subarnas AN. In situ ophthalmic gel with ion activated system. Int J App Pharm., 2019; 11(4): 15-8.
9. Ramyadevi D, Rajan KS, Vedhahari BN, Ruckmani K, Subramanian N. Heterogeneous polymer composite nanoparticles loaded in situ gel for controlled release intra-vaginal therapy of genital herpes. Colloids and Surfaces B: Biointerfaces, 2016 Oct 1; 146: 260-70.
10. Kabiri M, Kamal SH, Pawar SV, Roy PR, Derakhshandeh M, Kumar U, Hatzikiriakos SG, Hossain S, Yadav VG. A stimulus-responsive, in situ-forming, nanoparticle-laden hydrogel for ocular drug delivery. Drug delivery and translational research, 2018 Jun; 8: 484-95.
11. Žigrayová D, Mikušová V, Mikuš P. Advances in antiviral delivery systems and chitosan-based polymeric and nanoparticulate antivirals and antiviral carriers. Viruses, 2023 Feb 28; 15(3): 647.
12. Hatefi A, Amsden B. Biodegradable injectable in situ forming drug delivery systems. Journal of controlled release, 2002 Apr 23; 80(1-3): 9-28.
13. Gupta H, Velpandian T, Jain S. Ion-and pH-activated novel in-situ gel system for sustained ocular drug delivery. Journal of drug targeting, 2010 Aug 1; 18(7): 499-505.
14. Chen CC, Fang CL, Al-Suwayeh SA, Leu YL, Fang JY. Transdermal delivery of selegiline from alginate–Pluronic composite thermogels. International Journal of

Pharmaceutics, 2011 Aug 30; 415(1-2): 119-28.

15. Kabiri M, Kamal SH, Pawar SV, Roy PR, Derakhshandeh M, Kumar U, Hatzikiriakos SG, Hossain S, Yadav VG. A stimulus-responsive, in situ-forming, nanoparticle-laden hydrogel for ocular drug delivery. Drug delivery and translational research, 2018 Jun; 8: 484-95.
16. Destruel PL, Zeng N, Maury M, Mignet N, Boudy V. In vitro and in vivo evaluation of in situ gelling systems for sustained topical ophthalmic delivery: state of the art and beyond. Drug discovery today, 2017 Apr 1; 22(4): 638-51.
17. Paul S, Majumdar S, Chakraborty M. Revolutionizing ocular drug delivery: recent advancements in in situ gel technology. Bulletin of the National Research Centre, 2023 Oct 23; 47(1): 154.
18. Dhage AN, Mulla ZI, Kulkarni AS, Borge AR, Ghosalkar MK. In-situ gel-new formulation trend. Int J Sci Res Sci Technol, 2022 Nov; 9: 665-75.